Skip to main content

Dermatitis

Dermatology
4
Pipeline Programs
10
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Dermatology is a $292M market that is mature and consolidating, dominated by a single blockbuster approaching loss of exclusivity.

$0.292B marketMature→ Stable30 products15 companies

Key Trends

  • HUMIRA (adalimumab) dominates 88% of market spending but faces LOE in near-term, creating vulnerability
  • Novel mechanisms like aryl hydrocarbon receptor agonists gaining traction with emerging products in peak lifecycle
  • Substantial clinical trial activity (812 trials) suggests ongoing innovation pipeline despite mature market

Career Verdict

Dermatology offers stable near-term opportunities but requires strategic positioning given patent cliff risk and limited market size compared to other therapeutic areas.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1HUMIRADeclining
$258M
AbbVie·LOE_APPROACHING
#2VTAMAGrowing
$19M
Merck & Co.·PEAK13.5yr
#3ORACEADeclining
$4M
Galderma·LOE_APPROACHING1.6yr

Drug Class Breakdown

Unknown Mechanism (predominantly HUMIRA)
$258M(88%)

Patent cliff looming

Aryl Hydrocarbon Receptor Agonists
$19M(6%)

Emerging innovation

Retinoids and Derivatives
$3M(1%)

Mature segment

Other Mechanisms
$12M(4%)

Niche applications

Career Outlook

Stable

Dermatology represents a stable but narrow career path with limited growth compared to larger therapeutic areas; compensation is competitive in Commercial and Medical Affairs but R&D opportunities are scarce. HUMIRA's patent cliff creates near-term uncertainty for AbbVie but may drive restructuring and new product launches elsewhere. Market consolidation around a few large players (AbbVie, Regeneron, Merck) limits startup/biotech opportunities.

Breaking In

Enter via Commercial or Medical Affairs roles where hiring is highest; dermatology has lower scientific barrier to entry than oncology but requires strong relationship-building and market access acumen.

For Experienced Professionals

Leverage HUMIRA transition expertise or develop specialty in emerging mechanisms (retinoids, AhR agonists); consider moving to larger franchises (immunology, oncology) if seeking higher growth trajectory.

In-Demand Skills

Health Economics & Outcomes Research (HEOR)Dermatology Clinical KnowledgeSales Strategy & Account ManagementDigital Health / Telemedicine IntegrationMedical Writing for Topicals & Systemics

Best For

Regional Sales ManagerMedical Science Liaison (MSL)Product Manager (Post-Launch)Health Economics ManagerRegulatory Affairs Specialist

Hiring Landscape

$85K-$386K

Dermatology shows concentrated hiring at AbbVie (52 positions) and Regeneron (46 positions), with Commercial roles dominating (89 jobs, $188K avg salary) and Medical Affairs roles commanding premium compensation ($386K avg). Limited R&D hiring (8 positions) suggests mature drug development phase with emphasis on commercialization and market access.

173
Open Roles
3
Companies Hiring
3
Departments

Top Hiring Companies

53Growing
46Growing
14Stable

By Department

Commercial(51%)
$188K
Medical Affairs(24%)
$386K
Research & Development(5%)

Commercial and Medical Affairs roles offer strong compensation and growth, but overall job market is small; best for professionals seeking revenue-generating functions rather than discovery roles.

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
PF-04965842 100 mgPhase 31 trial
Active Trials
NCT03720470Completed838Est. Mar 2020
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Roflumilast creamPhase 21 trial
Active Trials
NCT00746382Withdrawn0Est. Sep 2009
ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
2
KLH 0.1 mgPhase 1
levocetirizinePhase 1
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
ADRN Barrier/Immunoprofiling Exploratory Pilot StudyN/A1 trial
Active Trials
NCT02115399Completed150Est. Jun 2015
Solventum
SolventumMN - St. Paul
1 program
Cavilon Advanced Barrier FilmN/A1 trial
Active Trials
NCT02724449Completed16Est. Feb 2015
Medica Corp
Medica CorpMA - Bedford
1 program
ChitoCare® medical Wound Healing GelN/A1 trial
Active Trials
NCT06850389Recruiting214Est. Dec 2025
Primex Pharmaceuticals
Primex PharmaceuticalsSwitzerland - Zug
1 program
ChitoCare® medical Wound Healing GelN/A
Innovation Pharmaceuticals
1 program
Patch TestN/A1 trial
Active Trials
NCT05891743Completed126Est. Oct 2024
GSK
GSKLONDON, United Kingdom
1 program
KLH 0.1 mgPHASE_11 trial
Active Trials
NCT01910662Completed24Est. Nov 2013
UCB Pharma
UCB PharmaBelgium - Brussels
1 program
LevocetirizinePHASE_31 trial
Active Trials
NCT00375713Completed466Est. May 2006

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerPF-04965842 100 mg
UCB PharmaLevocetirizine
AstraZenecaRoflumilast cream
GSKKLH 0.1 mg
Medica CorpChitoCare® medical Wound Healing Gel
Innovation PharmaceuticalsPatch Test
SolventumCavilon Advanced Barrier Film
Allergy TherapeuticsADRN Barrier/Immunoprofiling Exploratory Pilot Study

Clinical Trials (8)

Total enrollment: 1,834 patients across 8 trials

NCT03720470PfizerPF-04965842 100 mg

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Start: Oct 2018Est. completion: Mar 2020838 patients
Phase 3Completed
NCT00375713UCB PharmaLevocetirizine

Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema

Start: Oct 2005Est. completion: May 2006466 patients
Phase 3Completed
NCT00746382AstraZenecaRoflumilast cream

A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)

Start: Nov 2008Est. completion: Sep 20090
Phase 2Withdrawn
NCT01910662GSKKLH 0.1 mg

Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD)

Start: Feb 2013Est. completion: Nov 201324 patients
Phase 1Completed
NCT06850389Medica CorpChitoCare® medical Wound Healing Gel

PMCF Investigation of Medical Device ChitoCare® Medical

Start: Jun 2025Est. completion: Dec 2025214 patients
N/ARecruiting

Prevalence of Skin Sensitization and Dermatitis Among Epoxy-exposed Workers in the Wind Turbine Industry.

Start: Mar 2024Est. completion: Oct 2024126 patients
N/ACompleted
NCT02724449SolventumCavilon Advanced Barrier Film

A Clinical Evaluation of 3M Cavilon Advanced Barrier Film for the Treatment of Incontinence Associated Dermatitis (IAD)

Start: Aug 2014Est. completion: Feb 201516 patients
N/ACompleted
NCT02115399Allergy TherapeuticsADRN Barrier/Immunoprofiling Exploratory Pilot Study

ADRN Barrier/Immunoprofiling Exploratory Pilot Study

Start: Apr 2014Est. completion: Jun 2015150 patients
N/ACompleted

Related Jobs in Dermatology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 1,834 patients
10 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.